3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
20
Pain, Postoperative
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Neoplasms
4
Lung Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Myoma
3
Leiomyoma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Agnosia
3
Stomatitis
2
Skin Neoplasms
2
Postoperative Hemorrhage
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Hemorrhage
2
Fatigue
2
Colonic Neoplasms
2
Chronic Pain
2
Carcinoma, Hepatocellular
2
Water-Electrolyte Imbalance
1
Vulvodynia
1
Uterine Cervical Neoplasms
1
Interventions
pegfilgrastim
26
Filgrastim
24
Cyclophosphamide
8
Docetaxel
7
Etoposide
6
pegylated granulocyte colony-stimulating factor
5
Cytarabine
5
eflapegrastim
4
Granulocyte Colony-Stimulating Factor
4
Leucovorin
3
Fluorouracil
3
Doxorubicin
3
Cyclosporine
3
Cefepime
3
Caspofungin
3
Carboplatin
3
liposomal amphotericin B
2
Vincristine
2
Vancomycin
2
Topotecan
2
Methylprednisolone
2
Methotrexate
2
Itraconazole
2
Irinotecan
2
Ifosfamide
2
Idarubicin
2
Fluconazole
2
Daunorubicin
2
Cisplatin
2
Amikacin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts